en · de · es · pt
creatine-notes.peptides1004.com › Faq › Dihexa Chemical Identity And Origin — Reference Sheet

Dihexa Chemical Identity And Origin — Reference Sheet

By Editorial Desk · published 2026-01-30 · last reviewed 2026-03-02 · Faq

angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-02 and is reviewed periodically as new material appears.

Dihexa Chemical Identity and Origin

Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.

Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Handling and Quality Verification

Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.

Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.

Dihexa at a glance

PropertyValueNotes
Common nameDihexaShorthand used in research literature and supplier catalogs.
CAS Registry Number1401708-83-5Identifier assigned to the synthetic peptide.
Molecular formulaC27H44N4O5Reported formula; verify with a certificate of analysis.
AppearanceWhite to off-white powderTypical form for lyophilized research peptides.
Typical storage−20 °C or below, desiccatedCommon condition for peptide stability.

Mechanism And Laboratory Characterization

The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.

Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.

Related pages on this site

Background and Development History

Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.

Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.

Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.

Notes from published material

KOR agonist administration reduces both NREM and REM sleep while increasing sleep fragmentation across the sleep-wake cycle. Peripheral KOR activation drives sensory responses including cold allodynia and mechanical hypersensitivity through mechanisms distinct from central effects. In a mouse model, agonism of inhibitory, GABAergic KOR-containing neurons in the rostral ventromedial medulla activates a top-down mechanism of inhibiting pain and itch perception from the spinal cord simultaneously. KOR activation modulates immune cell trafficking, cytokine production, and inflammatory responses, implicating peripheral opioidergic signaling in immunoregulation. KOR agonists suppress itching, and the selective KOR agonist nalfurafine is used clinically as an antipruritic. KOR agonism is neuroprotective against hypoxia/ischemia in multiple experimental models. The selective KOR agonist U-50488 protected rats against supramaximal electroshock seizures, indicating that KOR agonism may have anticonvulsant effects.

== Structure–activity relationship == Even though μ-opioid receptor (MOR) targeting drugs have been used for a long time, not much is known about the structure-activity relationship and the ligand-receptor interactions on the basis of well-defined biological effects on receptor activation or inhibition. Also, the distinction in the receptor-ligand interaction patterns of agonists and antagonists is not known for sure. One theory states that the morphinans biological activity could be determined by the size of the N-substituents. For example, antagonists usually have larger substituents, such as allyl- or cyclopropyl methyl at the morphinan nitrogen, while agonists generally contain a methyl group. On the other hand, agonist activity is also shown in ligands with larger groups at the morphinan nitrogen, and therefore this hypothesis is challenged.

=== Comorbidities === The condition is strongly associated with or caused by type 2 diabetes, insulin resistance, and metabolic syndrome (defined as at least three of the five following medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein). It is also associated with:

=== Glucose–alanine cycle === In mammals, alanine plays a key role in glucose–alanine cycle between tissues and liver. In muscle and other tissues that degrade amino acids for fuel, amino groups are collected in the form of glutamate by transamination. Glutamate can then transfer its amino group to pyruvate, a product of muscle glycolysis, through the action of alanine aminotransferase, forming alanine and α-ketoglutarate. The alanine enters the bloodstream, and is transported to the liver. The alanine aminotransferase reaction takes place in reverse in the liver, where the regenerated pyruvate is used in gluconeogenesis, forming glucose which returns to the muscles through the circulation system. Glutamate in the liver enters mitochondria and is broken down by glutamate dehydrogenase into α-ketoglutarate and ammonium, which in turn participates in the urea cycle to form urea which is excreted through the kidneys. The glucose–alanine cycle enables pyruvate and glutamate to be removed from muscle and safely transported to the liver. Once there, pyruvate is used to regenerate glucose, after which the glucose returns to muscle to be metabolized for energy: this moves the energetic burden of gluconeogenesis to the liver instead of the muscle, and all available ATP in the muscle can be devoted to muscle contraction. It is a catabolic pathway, and relies upon protein breakdown in the muscle tissue. Whether and to what extent it occurs in non-mammals is unclear.

Sources: en.wikipedia.org

Further detail

The chain's 84 shops, located mainly in MTR and Kowloon–Canton Railway stations (as well as shopping centers and housing estates), were converted to 7-Eleven stores. In 2009, a 7-Eleven location in Quarry Bay opened with a hot food counter, called "7 Café", selling traditional Hong Kong street food and milk tea. This feature was subsequently extended to select other 7-Eleven locations across Hong Kong under the "Daily Café" and "Hot Shot" brands.

Brian Rafat Awadis (born November 19, 1996), formerly known online as FaZe Rug (simply known as Rug), is an American YouTuber who produces vlogs, challenges, gaming videos, and pranks on YouTube. A former co-owner of FaZe Clan and member for 13 years, he acquired his shares when the entertainment brand began distributing them to its biggest members. Awadis announced that he had left FaZe Clan through a post on X on December 27, 2025. Since then, he has pursued independent content on the YouTube platform.

During Bryson's 20-month tenure as Lilly's president and CEO, the company reported its first quarterly loss as a publicly traded company. In 1993, Randall L. Tobias, vice chairman of AT&T Corporation and a Lilly board member, was named Lilly's chairman, president, and CEO, the first president and CEO recruited from outside of the company. In 1994, Lilly separated its medical device division. It also acquired PCS Systems, the largest drug benefits health maintenance organization at the time, for $4 billion. Released in 1996, Zyprexa (Olanzapine) (for schizophrenia and bipolar disorder, as well as off-label uses) (see Illegal marketing of Zyprexa) was the company's best-selling drug through 2010, when the patent expired. In May 1996, the Food and Drug Administration approved gemcitabine (Gemzar) for the treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiation therapy. Gemzar is also routinely used to treat non-small cell lung cancer. In 1998, the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis. Sidney Taurel, former chief operating officer of Lilly, was named CEO in July 1998 to replace Tobias, who retired. Taurel became chairman of the board in January 1999. Taurel retired as CEO in March 2008, but remained as chairman of the board until 31 December 2008. John C. Lechleiter was elected as Lilly's CEO and president, effective 1 April 2008.

Sources: en.wikipedia.org

Supporting material

== Mass spectrometry == Generally this topic is discussed when covering tandem mass spectrometry fragmentation and occurs generally by the same mechanisms. For example, of a mechanism of alpha-cleavage, an electron is knocked off an atom (usually by electron collision) to form a radical cation. Electron removal generally happens in the following order: 1) lone pair electrons, 2) pi bond electrons, 3) sigma bond electrons. One of the lone pair electrons moves down to form a pi bond with an electron from an adjacent (alpha) bond. The other electron from the bond moves to an adjacent atom (not one adjacent to the lone pair atom) creating a radical. This creates a double bond adjacent to the lone pair atom (oxygen is a good example) and breaks/cleaves the bond from which the two electrons were removed.

Fluphenazine was the third antipsychotic FDA approved in the United States in 1959, and 9 years later was the first FDA approved injectable antipsychotic. The injectable form is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. It was discontinued in Australia in 2017.

Electron capture is sometimes included as a type of beta decay, because the basic nuclear process, mediated by the weak force, is the same. In electron capture, an inner atomic electron is captured by a proton in the nucleus, transforming it into a neutron, and an electron neutrino is released.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.

Where does dihexa come from?

It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.

Is dihexa the same as angiotensin IV?

No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.

How is dihexa stored in a laboratory?

Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.

Network